Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox InfectionGlobeNewsWire • 07/28/22
Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and DevelopmentGlobeNewsWire • 07/25/22
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive DisorderGlobeNewsWire • 07/11/22
Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USAGlobeNewsWire • 07/06/22
Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 06/22/22
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in MassachusettsGlobeNewsWire • 06/16/22
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant CongressGlobeNewsWire • 06/09/22
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for VirologyGlobeNewsWire • 06/08/22
Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for VirologyGlobeNewsWire • 06/08/22
Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International ConventionGlobeNewsWire • 06/06/22
Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant CongressGlobeNewsWire • 05/31/22